About the special issue
The World Health Organization has estimated that there were 38.4 million people living with HIV at the end of 2021, 1.5 million of whom were newly infected during that year . While there is no cure for HIV infection there are a number of antiretroviral therapies available which allow people living with HIV to lead a normal life and prevent further transmission. With improvements in drug efficacy and safety leading to new treatment options, it’s important to consider which therapy is best for each person.
This special issue on clinical pharmacology in people living with HIV in Expert Review of Clinical Pharmacology will highlight key innovations being made in the antiretroviral drug market and will include discussion of factors to consider when choosing the optimal treatments for people living with HIV. The issue will include a range of high-quality articles; original research papers and up-to-date review and perspective articles are welcomed. Topics of interest include, but are not limited to:
– Adverse effects/reactions, drug-drug and drug-disease interactions of existing and emerging antiretrovirals
– Clinical pharmacology of therapies for opportunistic infections and HIV-related cancers
– Clinical pharmacology of therapies for HIV and its comorbidities
– Conduct, design, and accessibility of antiretroviral therapy clinical trials
– HIV therapy in specific groups of people, such as children, older adults, and pregnant people
– Pharmacoeconomics, societal issues, and real-world evidence
If you are interested in contributing or would like to learn more, then please reach out to the Commissioning Editor, Alice Bough, with presubmission queries.